USPTO Examiner PROSSER ALISSA J - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17137370EYELASH LIQUID EYELINERDecember 2020April 2022Allow1500NoNo
17251015FLOWABLE CANNABINOID COMPOSITIONS HAVING HIGH EFFECTIVE CONCENTRATIONSDecember 2020March 2024Abandon3910NoNo
16972431COMPOSITION FOR DYEINGDecember 2020June 2023Abandon3021YesNo
16972219OIL-IN-WATER TYPE EMULSION COSMETIC USING PARTIALLY CROSSLINKED OR CROSSLINKED DIMETHYLPOLYSILOXANEDecember 2020June 2024Abandon4240NoNo
16981104MASSAGE CANDLE CONTAINING CANNABIDIOL OR ESSENTIAL OILDecember 2020December 2024Abandon5140NoNo
17109160PUMPKIN SEED PROTEIN NANOPARTICLES, METHODS FOR PREPARING AND USING THEREOFDecember 2020June 2022Allow1810NoNo
16952083METHOD FOR PRODUCING SOLID POWDER COSMETICNovember 2020May 2023Abandon3030NoNo
16952370ALCOHOL-BASED SPRAYABLE GEL WITH YIELD POINTNovember 2020November 2023Abandon3630NoNo
16766966METHOD FOR PRODUCING COSMETIC COMPOSITION COMPRISING NATURAL PLANT AND COSMETIC COMPOSITION PRODUCED THEREBYNovember 2020June 2025Abandon6041YesNo
16949647MASCARA FORMULATIONNovember 2020December 2022Abandon2510NoNo
17091166SKIN CARE COMPOSITIONS AND METHODS FOR MAKING THE SAMENovember 2020January 2023Abandon2711NoNo
17048432POWDEROUS COMPOSITION COMPRISING CAROTENOID AND/OR DERIVATIVE THEREOF, D-GLYCOSE OLIGOMERS AND MODIFIED POLYSACCHARIDE AS WELL AS FOOD, FEED OR PERSONAL CARE FORMULATION COMPRISING THE COMPOSITIONOctober 2020May 2024Abandon4320NoNo
17046860THICK WATER-BASED COSMETICOctober 2020July 2024Abandon4540YesNo
17060191Sincalide FormulationsOctober 2020July 2022Abandon2110NoNo
17038943HYDRATING NO-RINSE COMPOSITION FOR MAKEUP REMOVALSeptember 2020June 2025Abandon5651YesNo
17031546ANTIBACTERIAL ACTIVITY BY MG COMPLEX IN DEODORANT EMULSION FOR AEROSOLS, DEODORANT INCLUDING THE SAME AND USE OF THE DEODORANTSeptember 2020July 2022Abandon2110NoNo
16980435COMPOSITION FOR PURIFICATION OF BIOFLUIDSSeptember 2020October 2024Abandon4921YesNo
16979375WATER-RESISTANT COSMETIC COMPOSITIONSeptember 2020August 2023Abandon3641NoNo
17013541NAIL COATING REMOVER CREAM MASK AND THE METHOD OF USING THEREOFSeptember 2020September 2022Abandon2431YesNo
17010121COMPOSITE PARTICLES, METHOD OF PRODUCING COMPOSITE PARTICLES AND DRY POWDER OF COMPOSITE PARTICLES, SKIN APPLICATION COMPOSITION AND METHOD OF PRODUCING THE SKIN APPLICATION COMPOSITIONSeptember 2020April 2024Abandon4361YesYes
17006295STABILISED MULTIPLE EMULSIONS AS SKIN PROTECTION PRODUCTAugust 2020June 2024Abandon4550YesNo
16947418FORMULATIONS FOR VIROSOMESJuly 2020November 2022Abandon2830NoNo
16966816FUNCTIONAL POLYSACCHARIDE PARTICLEJuly 2020September 2022Abandon2511NoNo
16964618OILY COSMETIC AND METHOD FOR PRODUCING THE SAMEJuly 2020October 2023Abandon3941NoNo
16954027TOPICAL COMPOSITIONJune 2020November 2022Abandon2921NoNo
16894121FERRIC CITRATE DOSAGE FORMSJune 2020April 2023Abandon3541YesNo
16769559COSMETIC COMPOSITION FOR PROMOTING SKIN EXFOLIATIONJune 2020September 2023Abandon3931YesNo
16769456UV PROTECTION COSMETIC COMPOSITIONJune 2020April 2023Abandon3531NoNo
16768414HUMAN MILK OLIGOSACCHARIDES AND SYNTHETIC COMPOSITIONS THEREOF FOR MICROBIOTA MODULATIONMay 2020March 2025Abandon5841NoNo
16766400TOPICAL USE AND DELIVERY OF AMMONIA OXIDIZING MICROORGANISMSMay 2020November 2022Abandon3010NoNo
16764485SPECIAL POLYURETHANE UREA FOR INCREASING THE WATER RESISTANCE OF A SHAPED HAIRSTYLEMay 2020March 2023Abandon3411NoNo
16762296COMPOSITIONS AND METHODS FOR REPAIR OF SPLIT-ENDS IN HAIRMay 2020November 2024Abandon5421NoNo
16866739Compositions Comprising Oxidized CelluloseMay 2020August 2024Abandon5171NoNo
16861449COMPOSITIONS FOR SKIN EXPOLIATION AND USE THEREOFApril 2020September 2021Abandon1611NoNo
16862349METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC BETA-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOFApril 2020November 2023Abandon4360NoNo
16858815Sincalide FormulationsApril 2020January 2021Abandon810NoNo
16759084OIL-IN-WATER EMULSION COMPOSITION AND COSMETIC PREPARATIONApril 2020July 2022Abandon2611NoNo
16855697DEODORANT COSMETIC PRODUCTApril 2020January 2024Abandon4521NoYes
16853728TOPICALLY APPLICABLE CHEMICAL PEEL COMPOSITIONApril 2020June 2022Abandon2530NoNo
16754994Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic PlasticityApril 2020January 2022Abandon2121NoNo
16823768METHOD FOR DRY POWDER COATING CAPSULESMarch 2020February 2021Abandon1101NoNo
16648289SOLID W/O COSMETIC COMPOSITIONMarch 2020October 2024Allow5551YesNo
16648390ENCAPSULATION SYSTEM FOR PROLONGED RELEASE OF ACTIVE AGENTSMarch 2020October 2022Allow3131NoNo
16646904TABLET CONTAINING VALSARTAN AND SACUBITRILMarch 2020June 2023Abandon3941YesNo
16813769ANHYDROUS COSMETIC COMPOSITIONS AND USESMarch 2020April 2022Abandon2530NoNo
16641894STABLE LIQUID COMPOSITIONS OF PEMETREXEDFebruary 2020October 2021Abandon2011NoNo
16800069ANTIVIRAL PREPARATION FOR TREATING HUMAN SKINFebruary 2020September 2021Abandon1921YesNo
16640739NEW HAIR BOTOX MATERIAL AND THE METHOD TO APPLY THIS MATERIAL TO HAIRFebruary 2020August 2021Abandon1710NoNo
16635549LIFE-EXTENDING AGENT, ANTI-AGING AGENT, COSMETIC, AND FOOD/BEVERAGE COMPOSITIONJanuary 2020February 2021Abandon1201NoNo
16635343SOLID-PHASE SYNTHESIS OF PROTEIN-POLYMER CONJUGATES ON IMMOBILIZATION SUPPORTSJanuary 2020May 2024Abandon5201NoNo
16747946Fine Dry Particulate Retinoid Active Agent Compositions and Topical Formulations Including the SameJanuary 2020June 2021Abandon1721NoNo
16744760AQUEOUS COSMETIC COMPOSITION COMPRISING ALKYLCELLULOSEJanuary 2020August 2023Abandon4340NoYes
16743279COSMETIC COMPOSITION FOR UV-SCREENING WITH COOLING EFFECTJanuary 2020February 2022Abandon2530NoNo
16738294Flexible Gelatin Sealant Dressing with Reactive ComponentsJanuary 2020February 2023Abandon3741NoNo
16628439TOPICAL COMPOSITIONSJanuary 2020June 2021Abandon1821NoNo
16627539METHODS OF TREATING LIVER DISEASES ASSOCIATED WITH PORTAL TRACT OR PERIPORTAL INFLAMMATIONDecember 2019January 2022Abandon2421NoNo
16626159COSMETIC COMPOSITION COMPRISING AN ORDERED POROUS MATERIAL FOR REDUCING THE VISIBLE AND/OR TACTILE IRREGULARITIES OF THE SKINDecember 2019May 2025Abandon6071YesYes
16722412TOPICAL SKIN FORMULATIONDecember 2019January 2023Allow3740NoNo
16620639HYDROGEL BASED ENCAPSULATION DEVICEDecember 2019October 2021Abandon2221NoNo
16697856MAGNETIC COMPOSITION COMPRISING A POLYMER BLEND AND HIGH LOADING OF MAGNETIC MATERIALNovember 2019February 2024Abandon5161NoNo
16696289DRUG DEVICE COMBINATION FOR THE EFFECTIVE TREATMENT OF INCONTINENCE IN WOMENNovember 2019August 2021Abandon2120NoNo
16695498COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERSNovember 2019September 2024Abandon5751NoYes
16689280Method for enhancing anti-oxidation activity of a solution containing gold nanoclusters binding with ligands and its making processNovember 2019May 2021Abandon1820NoNo
16667238NATURALLY THICKENED COSMETIC CLEANING AGENTSOctober 2019August 2022Abandon3340NoNo
16606253METHOD FOR PRODUCING COATINGOctober 2019December 2024Abandon6041YesNo
16604698METHOD FOR PRODUCING COATINGOctober 2019November 2023Abandon4941NoNo
16589230Sincalide FormulationsOctober 2019August 2020Abandon1010NoNo
16500095DROPLET-RELEASING COSMETIC MATERIALOctober 2019June 2022Abandon3220NoNo
16494646COMPOSITIONS COMPRISING A FATTY PHASE AND AN AQUEOUS PHASE IN THE FORM OF SOLID SPHERESSeptember 2019October 2024Abandon6051NoNo
16564230POLYMERIC MICELLE CARRIER COMPOSITION AND POLYMERIC MICELLE COMPOSITIONSeptember 2019January 2020Abandon500NoNo
16565419METHOD OF PRODUCING EGGSHELL-DERIVED NANOPARTICLESSeptember 2019August 2020Allow1101YesNo
16562224ENTERIC COATED TIOPRONIN TABLETSeptember 2019July 2022Allow3470YesYes
16490585METHOD OF MANUFACTURING DERMATOLOGICALLY ACTIVE SUBSTANCE VEHICLE HAVING MULTILAYER STRUCTURE, AND COMPOSITION MATERIAL FOR FUNCTIONAL COSMETIC CONTAINING DERMATOLOGICALLY ACTIVE SUBSTANCE VEHICLE MANUFACTURED USING THE SAMESeptember 2019December 2022Abandon3921NoNo
16555190ADDITIVE FOR SOIL CONDITIONING AND AN AGRICULTURAL COMPOSITION CONTAINING SAID ADDITIVE FOR PLANT GROWTHAugust 2019December 2020Allow1621YesNo
16483699Sunscreen CompositionAugust 2019September 2022Abandon3731YesNo
16483071WATER-SOLUBILIZED MIXTURE OF GINSENOSIDE COMPOUND K AND METHOD OF WATERSOLUBILIZING GINSENOSIDE COMPOUND KAugust 2019November 2022Abandon3921NoNo
16508273PARTICLES, PHARMACEUTICAL PREPARATION, TOPICAL DRUG, AND COSMETIC PRODUCTJuly 2019June 2021Abandon2320NoNo
16438694TABLET CONTAINING FERRIC CITRATEJune 2019July 2021Abandon2511NoNo
16468599METHOD FOR PRODUCING CERAMIDE MICROPARTICLE DISPERSIONJune 2019November 2022Abandon4140YesNo
16417914HAIR CARE COMPOSITIONS AND METHODS OF MAKING AND USING SAMEMay 2019May 2023Allow4841YesNo
16417166STABILISED MULTIPLE EMULSIONS AS SKIN PROTECTION PRODUCTMay 2019December 2020Abandon1920NoNo
16410599HIGH CONCENTRATION SUSPENSION FORMULATION FOR COLD AND FLU SOFT GEL CAPSULE MEDICATIONSMay 2019October 2023Allow5451YesNo
16346529DISSOLVABLE FILMS AND METHODS OF THEIR USEApril 2019October 2022Abandon4121NoYes
16376907FERRIC CITRATE DOSAGE FORMSApril 2019December 2022Abandon4431NoNo
16337566COSMETIC COMPOSITIONS FOR COMBATTING COLOUR LOSS FROM A DYED MATERIALMarch 2019May 2024Allow6061NoNo
16352389METHOD FOR EVALUATING GLOW OF SKIN, METHOD FOR EXAMINING SKIN GLOW IMPROVERS, AND SKIN GLOW IMPROVERMarch 2019May 2022Abandon3831YesNo
16298771MASCARA FORMULATIONMarch 2019August 2020Allow1710NoNo
16295334NANOPARTICLES FOR DERMAL AND SYSTEMIC DELIVERY OF DRUGSMarch 2019November 2020Abandon2011NoNo
16330789Omeprazole FormulationsMarch 2019May 2022Abandon3831NoNo
16292409THIN FILM AND THIN FILM FORMING METHODMarch 2019October 2022Abandon4341YesNo
16293565PREFABRICATED PHARMACEUTICAL DOSAGE FORMS FROM FUNCTIONAL POLYMER FILMSMarch 2019November 2020Abandon2110NoNo
16249606BIODEGRADABLE SINGLE-PHASE COHESIVE HYDROGELSJanuary 2019July 2021Abandon3011NoNo
16239422CATALYTIC SYSTEMS INCLUDING A PEROXIDE FOR DELIVERY OF OXYGEN TO SKIN AND RELATED METHODS OF USEJanuary 2019January 2022Abandon3741YesNo
16204851COMPOSITIONS AND METHODS COMPRISING SALICYLATES AND POLYSALICYLATESNovember 2018September 2020Abandon2201NoNo
16202198Methods of Improving the Activity of RetinoidsNovember 2018January 2022Abandon3820NoYes
16154109UV-PROTECTIVE COMPOSITIONS AND THEIR USEOctober 2018July 2023Abandon5760YesYes
16151294Compositions, Methods and Uses for Improving a Skin or Hair RegionOctober 2018February 2021Abandon2821NoNo
16067894INTRAORAL RETENTIVE DISINTEGRATING SOLID PREPARATION, METHOD FOR PRODUCTION OF THE PREPARATION AND POWDER COMPOSITION TO BE USED IN SAID METHODSeptember 2018February 2023Abandon5641YesNo
16087039PHARMACEUTICAL SUSPENSION DOSAGE FORM OF BENZIMIDAZOLE COMPOUNDS AND PROCESS OF PREPARATION THEREOFSeptember 2018January 2021Allow2821NoNo
16131977METHOD OF INCREASING THE WASH RESISTANCE OF ARTIFICIALLY COLORED HAIRSeptember 2018January 2021Abandon2820NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PROSSER, ALISSA J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
36
Examiner Affirmed
30
(83.3%)
Examiner Reversed
6
(16.7%)
Reversal Percentile
27.9%
Lower than average

What This Means

With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
97
Allowed After Appeal Filing
9
(9.3%)
Not Allowed After Appeal Filing
88
(90.7%)
Filing Benefit Percentile
13.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 9.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PROSSER, ALISSA J - Prosecution Strategy Guide

Executive Summary

Examiner PROSSER, ALISSA J works in Art Unit 1619 and has examined 429 patent applications in our dataset. With an allowance rate of 16.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner PROSSER, ALISSA J's allowance rate of 16.6% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PROSSER, ALISSA J receive 3.29 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PROSSER, ALISSA J is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +14.9% benefit to allowance rate for applications examined by PROSSER, ALISSA J. This interview benefit is in the 53% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 3.4% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 11.2% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 35.7% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 45.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 86.2% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.